Phase II Study of Weekly Doxorubicin Treatment of AIDS Associated Kaposi's Sarcoma

Inclusion Criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

- Ongoing and/or maintenance therapy for opportunistic infection.

- Medications for nausea, vomiting, and diarrhea resulting from drug.

Patients must have AIDS related Kaposi's sarcoma.

- Patients may demonstrate positive blood cultures for Mycobacterium avium-complex or
cytomegalovirus.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions will be excluded:

- Patients with active opportunistic infection.

- Patients with concurrent neoplasm other than squamous cell carcinoma of the skin or
in situ carcinoma of the cervix.

- Patients with significant neurologic, cardiac, or liver disease.

Concurrent Medication:

Excluded:

- Antiretroviral agents.

- Immunomodulators.

- Corticosteroids.

- Experimental drugs.

The following patients will be excluded from the study:

- Patients with lymphadenopathy alone and/or visceral disease alone secondary to
Kaposi's sarcoma.

Prior Medication:

Excluded:

- Cytotoxic chemotherapy.

- Excluded within 30 days of study entry:

- Antiretroviral agents.

- Biologic modifiers.

- Corticosteroids.

Prior Treatment:

Excluded:

- Total body electron beam therapy.

- Excluded within 30 days of study entry:

- Radiation therapy.